Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

72.38 +0.10 (+0.14%)
Delayed Quote Updated: 11:45 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu... 
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Ignore
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
3 Profitable Stocks Worth Investigating
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financia... 
Via StockStory
News headline image
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S... 
Via StockStory
ANI Pharmaceuticals (NASDAQ:ANIP) Tumbles on Weak Guidance Despite Q2 EPS Beat ↗
Via Chartmill
News headline image
2 Cash-Producing Stocks to Target This Week and 1 We Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
2 Value Stocks on Our Watchlist and 1 We Find Risky
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
2 Reasons to Like ANIP (and 1 Not So Much)
ANI Pharmaceuticals currently trades at $76.15 per share and has shown little upside over the past six months, posting a middling return of 3%. The stock als... 
Via StockStory
Topics Supply Chain
News headline image
1 Russell 2000 Stock to Target This Week and 2 We Brush Off
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou... 
Via StockStory
News headline image
ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript ↗
Rare disease revenue surged 43.5% as Cortrophin Gel sales accelerated across key specialties. 
Via The Motley Fool
Topics Earnings
News headline image
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call
ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively t... 
Via StockStory
Topics Earnings
News headline image
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 25.9... 
Via StockStory
News headline image
ANI Pharmaceuticals Q2 Earnings Call Highlights ↗
ANI Pharmaceuticals (NASDAQ:ANIP) reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the... 
Via MarketBeat
Topics Earnings
News headline image
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 25.9% ... 
Via StockStory
Topics Earnings
News headline image
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings tomorrow before the bell. Here’s what to look for. ANI Pharmace... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Healthcare Stock Worth Your Attention and 2 We Question
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
News headline image
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as... 
Via StockStory
News headline image
2 Reasons to Watch ANIP and 1 to Stay Cautious
Since January 2026, ANI Pharmaceuticals has been in a holding pattern, posting a small loss of 3.5% while floating around $78.49. The stock also fell short o... 
Via StockStory
News headline image
2 Small-Cap Stocks Worth Investigating and 1 We Brush Off
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run ↗
Carey exercised vested options under a pre-established Rule 10b5-1 trading plan adopted in March, retaining 177,543 directly held shares. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
2 Value Stocks for Long-Term Investors and 1 We Avoid
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge ↗
This specialty pharma company, known for its branded and generic drug portfolio, just reported a notable insider sale in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 of Wall Street’s Favorite Stocks to Target This Week
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
2 Cash-Producing Stocks to Research Further and 1 Facing Challenges
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Ani (ANIP) Q1 2026 Earnings Call Transcript ↗
Ani (ANIP) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
2 Growth Stocks with Explosive Upside and 1 We Avoid
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.